Admin Table of Contents
Can you still get sibutramine?
Sibutramine was a widely used weight loss treatment before being withdrawn in the United Kingdom in 2010 due to safety concerns that it could potentially increase the risk of strokes or heart attacks. Its use has also been suspended in the United States, Europe and China.
How effective is sibutramine?
At 1 year, adults receiving sibutramine, 10 to 15 mg/d, lost an average of 4.5 kg (9.8 pounds) more than adults receiving placebo. Adults taking sibutramine for 1 year are 19% to 34% more likely to achieve 5% weight loss and 12% to 31% more likely to achieve 10% weight loss than those taking placebo.
What vitamins should I take with orlistat?
Orlistat blocks your body’s absorption of some fat-soluble vitamins and beta carotene. Therefore, when you use orlistat you should take a daily multivitamin that contains vitamins A, D, E, K, and beta-carotene. Read the label to find a multivitamin product that contains these vitamins.
How is sibutramine used to treat weight loss?
Sibutramine affects chemicals in the brain that affect weight maintenance. Sibutramine is used together with diet and exercise to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure. Sibutramine may also be used for other purposes not listed in this medication guide.
Who is the manufacturer of sibutramine in the UK?
Sibutramine was originally developed in 1988 by Boots in Nottingham, UK, and marketed by Knoll Pharmaceuticals after BASF/Knoll AG purchased the Boots Research Division in 1995, and was most recently manufactured and marketed by Abbott Laboratories before its withdrawal from most markets.
Are there any side effects to taking sibutramine?
Less serious side effects may include: flu symptoms, runny or stuffy nose, sore throat, cough; warmth, redness, or tingly feeling under your skin; mild skin rash. This is not a complete list of side effects and others may occur.
Why did Abbott withdraw sibutramine from the market?
Abbott Laboratories announced on October 8, 2010 that it is withdrawing sibutramine from the US market under pressure from the FDA, citing concerns over minimal efficacy coupled with increased risk of adverse cardiovascular events.